Arvinas, Inc. (NASDAQ:ARVN) Receives Average Rating of "Moderate Buy" from Analysts

Arvinas, Inc. (NASDAQ:ARVN - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the sixteen analysts that are currently covering the company, Marketbeat Ratings reports. Five equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. The average 1 year price objective among analysts that have covered the stock in the last year is $34.53.

ARVN has been the subject of several analyst reports. Morgan Stanley decreased their price objective on shares of Arvinas from $48.00 to $12.00 and set an "equal weight" rating for the company in a research note on Thursday, March 13th. BMO Capital Markets set a $20.00 price objective on Arvinas and gave the company an "outperform" rating in a report on Wednesday, March 12th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Arvinas in a research report on Friday, February 7th. HC Wainwright reiterated a "buy" rating and set a $81.00 target price on shares of Arvinas in a research report on Monday. Finally, Stifel Nicolaus cut their price target on shares of Arvinas from $63.00 to $51.00 and set a "buy" rating on the stock in a report on Wednesday, February 12th.

Insider Buying and Selling

In other Arvinas news, CEO John G. Houston sold 31,338 shares of the business's stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $16.72, for a total value of $523,971.36. Following the completion of the transaction, the chief executive officer now directly owns 1,157,480 shares in the company, valued at approximately $19,353,065.60. The trade was a 2.64 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Ian Taylor sold 9,020 shares of the stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $16.71, for a total transaction of $150,724.20. Following the sale, the insider now directly owns 159,121 shares of the company's stock, valued at approximately $2,658,911.91. The trade was a 5.36 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 50,230 shares of company stock valued at $769,402 over the last 90 days. Corporate insiders own 5.23% of the company's stock.

Hedge Funds Weigh In On Arvinas

Several hedge funds and other institutional investors have recently modified their holdings of ARVN. T. Rowe Price Investment Management Inc. purchased a new stake in Arvinas during the 4th quarter valued at about $42,332,000. Norges Bank acquired a new stake in shares of Arvinas during the fourth quarter worth about $23,845,000. Boxer Capital Management LLC purchased a new stake in Arvinas in the fourth quarter valued at approximately $20,294,000. RTW Investments LP increased its holdings in Arvinas by 19.8% in the 4th quarter. RTW Investments LP now owns 3,334,308 shares of the company's stock worth $63,919,000 after buying an additional 551,979 shares during the period. Finally, ArrowMark Colorado Holdings LLC raised its position in Arvinas by 42.8% during the 4th quarter. ArrowMark Colorado Holdings LLC now owns 1,776,555 shares of the company's stock worth $34,057,000 after buying an additional 532,105 shares during the last quarter. 95.19% of the stock is owned by hedge funds and other institutional investors.

Arvinas Stock Down 1.6 %

ARVN traded down $0.11 during trading on Friday, reaching $6.62. The company had a trading volume of 2,271,611 shares, compared to its average volume of 1,078,795. The business has a 50 day simple moving average of $12.80 and a 200-day simple moving average of $19.30. The stock has a market cap of $455.27 million, a P/E ratio of -2.39 and a beta of 2.30. Arvinas has a 52 week low of $5.94 and a 52 week high of $39.34.

Arvinas (NASDAQ:ARVN - Get Free Report) last announced its earnings results on Tuesday, February 11th. The company reported ($0.63) earnings per share for the quarter, beating the consensus estimate of ($1.07) by $0.44. Arvinas had a negative net margin of 75.51% and a negative return on equity of 33.75%. During the same period in the prior year, the company earned ($2.53) EPS. As a group, equities research analysts expect that Arvinas will post -3.81 EPS for the current fiscal year.

About Arvinas

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.